European Medicines Agency (EMA) completes its review of Avastin (bevacizumab) used in breast cancer treatment
20 December 2010
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that Avastin, when used to treat metastatic breast cancer, should only be used in combination with the taxane paclitaxel. This follows a review of Avastin in combination with taxanes, where the Committee concluded that Avastin should no longer be used in combination with another taxane, docetaxel. The Committee also adopted a negative opinion on the proposed use of Avastin in combination with capecitabine in metastatic breast cancer.
Further information, including recommendations for patients and prescribers, is available at the links below:
Press release on European Medicines Agency website
Q & A document on European Medicines Agency website